Search research articles
Contact Us
Filters
Showing results (261-270 of 471) with videos related to
Page
of 48
Sort By:
JAMA Cardiology
|
November 29, 2018
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial
Pratyaksh K Srivastava, Brian L Claggett, Scott D Solomon, et al.
European Journal of Heart Failure
|
May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction
Kota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Cardiovascular Drugs and Therapy
|
September 27, 2017
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
Søren L Kristensen, Pardeep S Jhund, Matthew M Y Lee, et al.
Journal of the American College of Cardiology
|
April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
Circulation
|
August 29, 2007
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
Scott D Solomon, Joanna Dobson, Stuart Pocock, et al.
JACC. Heart Failure
|
April 29, 2017
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials
Milton Packer, John J V McMurray, Henry Krum, et al.
Circulation. Heart Failure
|
October 19, 2014
Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction
Akshay S Desai, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure
|
February 24, 2007
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
Nathaniel M Hawkins, Duolao Wang, John J V McMurray, et al.
Heart (British Cardiac Society)
|
January 24, 2007
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Christian Torp-Pedersen, Marco Metra, Andrew Charlesworth, et al.
Journal of the American College of Cardiology
|
February 21, 2006
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
John McMurray, Scott Solomon, Karen Pieper, et al.
Page
of 48
Search research articles
Search
Showing results (261-270 of 471) with videos related to
Sort By:
Page
of 48
JAMA Cardiology
|
November 29, 2018
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial
Pratyaksh K Srivastava, Brian L Claggett, Scott D Solomon, et al.
European Journal of Heart Failure
|
May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction
Kota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Cardiovascular Drugs and Therapy
|
September 27, 2017
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
Søren L Kristensen, Pardeep S Jhund, Matthew M Y Lee, et al.
Journal of the American College of Cardiology
|
April 25, 2006
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, et al.
Circulation
|
August 29, 2007
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
Scott D Solomon, Joanna Dobson, Stuart Pocock, et al.
JACC. Heart Failure
|
April 29, 2017
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials
Milton Packer, John J V McMurray, Henry Krum, et al.
Circulation. Heart Failure
|
October 19, 2014
Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction
Akshay S Desai, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure
|
February 24, 2007
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
Nathaniel M Hawkins, Duolao Wang, John J V McMurray, et al.
Heart (British Cardiac Society)
|
January 24, 2007
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Christian Torp-Pedersen, Marco Metra, Andrew Charlesworth, et al.
Journal of the American College of Cardiology
|
February 21, 2006
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
John McMurray, Scott Solomon, Karen Pieper, et al.
Page
of 48